Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
Progressive Weakness with Respiratory Failure in a Patient with Sarcoidosis
Arch Neurol 69:534-537, Chaudhry,P.,et al, 2012
Respiratory Adverse Events Associated with Diazepam Rectal Gel
Neurol 64:1768-1770, Pellock,J.M. &Shinnar,S., 2005
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Complications of Sedation with Midazolam in the Intensive Care Unit and a Comparison with Other Sedative Regimens
Crit Care Med 26:947-956, Shafer,A., 1998
Coma Induced by Abuse of Gamma-Hydroxybutyrate (GBH or Liquid Ecstasy) :A Case Report
BMJ 314:35-36, Thomas,G.,et al, 1997
Side Effect Profile of Interferon Beta-1b in MS:Results of an Open Label Trial
Neurol 46:552-554, Neilley,L.K.,et al, 1996
Missed Neuroleptic Malignant Syndrome
BMJ 304:831-832, Renwick,D.S.,et al, 1992
Prolonged Weakness after Long-Term Infusion of Vecuronium Bromide
Ann Int Med 117:484-486, Kupfer,Y.,et al, 1992
Multistate Outbreak of Poisonings Associated with Illicit Use of Gamma Hydroxy Butyrate
JAMA 265:447-448, , 1991
Eosinophilia-Myalgia Syndrome, A Clinical Case Series of 21 Patients
Arch Int Med 151:533-537, Philen,R.M.,et al, 1991
Aggravation of Myasthenia Gravis by Erythromycin
J Pediatr 119:155-156, Absher,J.R.&Bale,J.F., 1991
Prolonged Paralysis after Treatment with Neuromuscular Junction Blocking Agents
Crit Care Med 19:1125-1131, Gooch,J.L.,et al, 1991
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991
Irregular Breathing
In Internal Medicine, Little, Brown & Co, Boston, 3rd Ed, p. 573-574, Cherniack,N.S., 1990
Clinical Use and Toxicity of Intravenous Lidocaine, A Report from the Boston Collaborative Drug Surveillance Program
Am Heart J 92:168-173, Pfeifer,H.J.,et al, 1976
Cannabis-Related Disorders and Toxic Effects
NEJM 389: 2267-2275, Gorelick,D.A., 2023
Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies
Neurol 99:654-657, Urso, D.,et al, 2022
Tardive Diaphragmatic Tremor
Neurol 94:e656, Gupta, H.V., 2020
Clinicopathologic Conference, Digitalis Toxicity
NEJM 378:1931-1938, Case 15-2018, 2018
Migraine
NEJM 377:553-561, Charles, A., 2017
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
A 35-Year-Old Man with 2 Episodes of Meningoencephalitis Associated with Flu-Like Illness
Neurol 84:e60-e64, Lewis, S.L., 2015
Synthetic Cannabinoid-Related Illnesses and Deaths
NEJM 373:103-107, Trecki, J.,et al, 2015
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Suicide-Related Events in Patients Treated With Antiepileptic Drugs
NEJM 363:542-551, Arana,A., et al, 2010
Polymyalgia Rheumatica
BMJ 336:765-769, Michet,C.J. &Matteson,E.L., 2008
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease
NEJM 355:1525-1538,1604, Schneider,L.S.,et al, 2006
Psychotropic Effects of Antiepileptic Drugs
Neurol 67:1916-1925, Ettinger,A.B., 2006
Psychosis Related to Ropinirole
Am J Psychiatry 163:546-547, Perea,E.,et al, 2006
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Cerebral Toxoplasmosis Following Etanercept Treatment for Idiophatic Pneumonia Syndrome after Autologous Peripheral Blood Progenitor Cell Transplantation (PBPCT)
Ann Hematol 82:649-653, Gonzalez-Vicent, M.,et al, 2003
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Prolongation of Midazolam Half-Life After Sustained Infusion for Status Epilepticus
Neurol 54:1366-1368, Naritoku,D.K.&Sinha,S., 2000
Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000
Serotonin Sydrome
Medicine 79:201-209, Mason,P.J. et al, 2000
Treatment of Drug-Induced Psychosis with Quetiapine and Clozapine in Parkinson's Disease
Neurol 55:1753-1754, Dewey,R.B.Jr. & O'Suilleabhain,P.E., 2000
Central Anticholinergic Syndrome on Therapeutic Doses of Cyproheptadine
Pediatrics 103:158-160, Watemberg,N.M.,et al, 1999
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Ibuprofen Treatment Versus Gradual Introduction of Interferon B-1b in patients with MS
Neurol 52:1893-1895, Rice,G.P.A.,et al, 1999
Transderm-induced Psychosis in Parkinson's Disease
Neurol 53:433-434, Minagar,A.,et al, 1999
Diagnosing Dementia with Lewy Bodies
Lancet 354:1227-1228, McKeith,I.G.,et al, 1999
Psychiatric Adverse Events During Vigabatrin Therapy
Neurol 53:1503-1511, Levinson,D.F.&Devinsky,O., 1999
Low-Dose Steroids Reduce Flu-Like Symptoms at the Initiation of INFB-1b in Relapsing-Remitting MS
Neurol 50:1910-1912, Rio,J.,et al, 1998